| Trial ID: | L3033 |
| Source ID: | NCT01440257
|
| Associated Drug: |
Placebo
|
| Title: |
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetic Nephropathy|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Placebo|DRUG: CCX140-B
|
| Outcome Measures: |
Primary: Change from baseline in 24-hour urinary albumin excretion, The primary efficacy objective of this study is to evaluate the effect of CCX140-B treatment on urinary albumin excretion by measuring change from baseline in 24-hour urinary albumin excretion., 84 days|Subject incidence of adverse events, The primary safety objective of this study is to evaluate the safety and tolerability of CCX140-B in subjects with type 2 diabetes mellitus (T2DM) with albuminuria., 84 days | Secondary: Change from baseline in hemoglobin A1c, 84 days
|
| Sponsor/Collaborators: |
Sponsor: Amgen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2011-09
|
| Completion Date: |
2013-09
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-27
|
| Locations: |
Centre for Human Drug Research, Leiden, Netherlands
|
| URL: |
https://clinicaltrials.gov/show/NCT01440257
|
